Kristine Crews, PharmD

Kristine R. Crews, PharmD

Translational Research Laboratory Director
Co-director, Pharmacokinetics Shared Resource
Director, PGY2 Pharmacogenetics Residency Program
Department of Pharmaceutical Sciences

Contact Information

Kristine R. Crews, PharmD, BCPS
Pharmaceutical Sciences
St. Jude Children's Research Hospital
Mail Stop 313
262 Danny Thomas Place
Memphis, TN 38105-3678
Phone: (901) 595-3338
FAX: (901) 595-8869


BS - Rutgers, The State University of New Jersey, New Brunswick
PharmD - Rutgers, The State University of New Jersey, New Brunswick
Residency - Clinical Pharmacokinetics, University of Kentucky Medical Center, Lexington
Fellowship - Clinical Pharmacokinetics/Pharmacodynamics and Drug Development, University of North Carolina School of Pharmacy, Chapel Hill and Glaxo Wellcome, Inc., Research Triangle Park, North Carolina

Honors and Awards

Research Interests

Selected Publications

Hicks JK, Crews KR, Flynn P, Haidar CE, Daniels C, Yang W, Pei D, Scott JR, Molinelli A, Broeckel U, Evans WE, Relling MV. Correlation of CYP2C19 genetic variants with voriconazole plasma concentrations in immunocompromised pediatric patients. Pharmacogenomics 2014 (in press).

Bhatia S, Landier W, Hageman L, Kim H, Chen Y, Crews KR, Evans WE, Bostrom B, Casillas J, Dickens DS, Maloney KW, Neglia JP, Ravindranath Y, Ritchey K, Wong FL, Relling MV. Adherence to oral 6-mercaptopurine in African American and Asian children with acute lymphoblastic leukemia – A Children’s Oncology Group Study. Blood 2014 May 14 [Epub ahead of print].

Crews KR, Gaedigk A, Dunnenberger HM, Leeder JS, Klein TE, Caudle KE, Haidar CE, Shen DD, Callaghan JT, Sadhasivam S, Prows CA, Kharasch ED, Skaar TC. Clinical Pharmacogenetics Implementation Consortium guidelines for for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther 95:376-82, 2014.

Hoffman JM, Haidar CE, Wilkinson MR, Crews KR, Baker DK, Kornegay NM, Yang W, Pui CH, Reiss UM, Gaur AH, Howard SC, Evans WE, Broeckel U, Relling MV. PG4KDS: A model for the clinical implementation of preemptive pharmacogenetics. Amer J Med Genet Part C 166C:45-55, 2014.

Caudle KE, Klein TE, Hoffman JM, Muller DJ, Whirl-Carrillo M, McDonagh EM, Sangkuhl K, Thorn CF, Schwab M, Agundez JAG, Freimuth RR, Huser V, Lee MTM, Iwuchukwu OF, Crews KR, Scott SA, Wadelius M, Swen JJ, Stein CM, Roden D, Relling MV, Williams MS, Johnson SG. Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab 15:209-17, 2014.

Bell GC, Crews KR, Wilkinson MR, Haidar CE, Hicks JK, Baker DK, Kornegay NM, Yang W, Cross SJ, Howard SC, Freimuth RR, Evans WE, Broeckel U, Relling MV, Hoffman JM. Development and use of active clinical decision support for preemptive pharmacogenomics. J Am Med Inform Assoc 21(e1):e93-99, 2014. (PMID23978487)

Scott JR, Ward DA, Crews KR, Panetta JC, Relling MV, Navid F. Hypersensitivity reaction to high-dose methotrexate and successful rechallenge in a pediatric patients with osteosarcoma. Pediatr Blood Cancer 61:373-5, 2014.

Pauley JL, Panetta JC, Crews KR, Pei D, Cheng C, McCormick J, Howard SC, Sandlund JT, Jeha S, Ribeiro RC, Rubnitz JE, Pui CH, Evans WE, Relling MV. Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments. Cancer Chemother Pharmacol 72:369-78, 2013.

Cao X, Mitra AK, Pounds S, Crews KR, Gandhi V, Plunkett W, Dolan ME, Hartford C, Raimondi S, Campana D, Downing J, Rubnitz JE, Ribeiro RC, Lamba JK. RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients. Pharmacogenomics 14:1449-66, 2013.

Bernardo VA, Cross SJ, Crews KR, Flynn PM, Hoffman JM, Knapp KM, Pauley JL, Molinelli AR, Greene WL. Posaconazole therapeutic drug monitoring in pediatric patients and young adults with cancer. Ann Pharmacother 47:976-83, 2013.

Evans WE, Crews KR, Pui CH. A healthcare system perspective on implementing genomic medicine: Pediatric acute lymphoblastic leukemia as a paradigm. Clin Pharmacol Ther 94:224-9, 2013.

Stocco G, Yang W, Crews KR, Thierfelder WE, Decorti G, Londero M, Franca R, Rabusin M, Grazia Valsecchi M, Pei D, Cheng C, Paugh SW, Ramsey LB, Diouf B, McCorkle JR, Jones TS, Pui CH, Relling MV, Evans WE. PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity. Hum Mol Genet 21:4793-804, 2012.

Hicks JK, Crews KR, Hoffman JM, Kornegay NM, Wilkinson MR, Lorier R, Yang W, Smith C, Fernandez CA, Cross SJ, Haidar CE, Baker DK, Howard S, Evans WE, Broeckel U, Relling MV. A clinician-driven automated system for integration of pharmacogenetic interpretations into an electronic medical record. Clin Pharmacol Ther 92:563-6, 2012.(PMCID:PMC3589522)

Crews KR, Hicks JK, Pui CH, Relling MV, Evans WE. Pharmacogenomics and individualized medicine: Translating science into practice. Clin Pharmacol Ther 92:467-75, 2012.

Fernandez CA, Smith C, Yang W, Lorier R, Crews KR, Kornegay N, Hicks JK, Stewart CF, Kawedia JD, Ramsey LB, Liu C, Evans WE, Relling MV, Broeckel U. Concordance of DMET Plus genotypes with orthogonal genotyping methods. Clin Pharmacol Ther 92:360-5, 2012.

Liu C, Kawedia JD, Cheng C, Fernandez CA, Cai X, Crews KR, Kaste SC, Panetta JC, Bowman WP, Jeha S, Sandlund JT, Evans WE, Pui CH, Relling MV. Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. Leukemia 26:2303-9, 2012.

Christensen, AM, Pauley JL, Molinelli AR, Panetta JC, Ward DA, Stewart CF, Hoffman JM, Howard SC, Pui CH, Pappo AS, Relling MV, Crews KR. Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients. Cancer 118:4321-30, 2012.

Stocco G, Crews KR. Pharmacogenetics, cost of genotyping and guidelines for individualizing therapy with mercaptopurine in pediatric acute lymphoblastic leukemia (letter). Pediatr Blood Cancer 57:1247, 2011.

Mitra AK, Crews KR, Pounds S, Cao X, Feldberg T, Ghodke Y, Gandhi V, Plunkett W, Dolan ME, Hartford C, Raimondi S, Campana D, Downing J, Rubnitz JE, Ribeiro RC, Lamba JK. Genetic variants in NT5C2 are associated with its expression and cytarabine sensitivity in HapMap cell lines and in AML patients. J Pharmacol Exp Ther 339:9-23, 2011.

Paugh SW, Stocco G, McCorkle JR, Diouf B, Crews KR, Evans WE. Cancer pharmacogenomics. Clin Pharmacol Ther 90:461-6, 2011.

McGregor LM, Stewart CF, Crews KR, Tagen M, Wozniak A, Wu J, McCarville B, Navid F, Spunt SL, Santana VM, Furman WL, Rodriguez Galindo C. Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors. Pediatr Blood Cancer 58:372-9, 2012.

Mitra AK, Crews KR, Pounds S, Cao X, Downing JR, Raimondi S, Campana D, Ribeiro RC, Rubnitz JE, Lamba JK. Impact of genetic variation in FKBP5 on clinical response in pediatric acute myeloid leukemia patients: a pilot study. Leukemia 25:1354-6, 2011.

Lamba JK, Crews KR, Pounds SB, Cao X, Gandhi V, Plunkett W, Razzouk BI, Lamb V, Baker SD, Raimondi SC, Campana D, Pui CH, Downing JR, Rubnitz JE, Ribeiro RC. Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes. Pharmacogenomics 12:327-39, 2011.

Crews KR, Cross SJ, McCormick JM, Baker DK, Molinelli AR, Mullins R, Relling MV, Hoffman JM. Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Amer J Health-Syst Pharm 68: 143-50, 2011.

Stocco G, Crews KR, Evans WE. Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl transferase status. Expert Opin Drug Saf 9: 23-37, 2010.

Inaba H, Stewart CF, Crews KR, Pounds S, Pui CH, Rubnitz JE, Razzouk BI, Ribeiro RC. Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia. Cancer 116:98-105, 2010.

Crews KR, Zhou Y, Pauley J, Howard SC, Jeha S, Relling MV, Pui CH. Effect of allopurinol versus urate oxidase on methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia. Cancer 116:227-32, 2010.